Entera Bio Reports Rapid Pharmacodynamic Response And Consistent Pharmacokinetic Data For Its First-In-Class Oral PTH(1-34) Mini Tablets At The ASBMR 2023 Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Entera Bio Ltd. (NASDAQ:ENTX) presented two posters at the Annual Society of Bone and Mineral Research (ASBMR) 2023 Annual Meeting, showcasing the consistent delivery and rapid biological responses of its oral PTH(1-34) peptide in a mini tablet format. The company's lead drug candidate, EB613, is being developed as a once-daily oral therapy for osteoporosis. A Phase 2 study showed that EB613 produced rapid changes in biochemical markers and increased Bone Mineral Density in postmenopausal women with osteoporosis. A Phase 1 study comparing oral EB613 and other treatments is ongoing.
October 16, 2023 | 12:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Entera Bio Ltd. presented promising data on its oral PTH(1-34) peptide and its lead drug candidate, EB613, at the ASBMR 2023 Annual Meeting. This could potentially boost investor confidence in the company's product pipeline.
The presentation of positive data on Entera Bio's products at a major conference could potentially increase investor confidence in the company's product pipeline and its ability to deliver effective treatments. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100